Abstract: The impact of adding bevacizumab to perioperative chemotherapy in patients with colorectal cancer (CRC) undergoing liver resection is yet to be defined.A retrospective review of our patient records showed that the addition of bevacizumab did not increase morbidity or mortality related to liver resection.Pathologic complete response (CR) is associated with prolonged survival.